A simplified mathematical-computational model of the immune response to the yellow fever vaccine

An effective yellow fever vaccine has been available since 1937. However, some issues regarding its use remain open, such as the minimum dose that can provide immunity against the disease. Mathematical-computational tools can be useful to assist the search for answers to some of these open issues. In this context, this study presents a simplified mathematical-computational model of the human immune response to the vaccination against yellow fever that takes into account important cells of the immune system. The model was able to qualitatively reproduce some experimental results reported in the literature, such as the amount of antibodies and viremia along time, as well as to reproduce distinct behaviors of the immune response reported in the literature. This is the first step towards an ideal scenario where it will be possible to simulate distinct situations related to the use of the yellow fever vaccine, such as its application in immunodeficient individuals, different vaccination strategies, duration of immunity and the need for a booster dose.

[1]  D. Flower,et al.  Quantitative approaches to computational vaccinology , 2002, Immunology and cell biology.

[2]  Mauro Magnani,et al.  Selection of Vaccine Candidates for Fish Pasteurellosis Using Reverse Vaccinology and an In Vitro Screening Approach. , 2016, Methods in molecular biology.

[3]  S Lopes Ode,et al.  Studies on yellow fever vaccine. III--Dose response in volunteers. , 1988, Journal of biological standardization.

[4]  Alex G. Taranto,et al.  The Use of Reverse Vaccinology and Molecular Modeling Associated with Cell Proliferation Stimulation Approach to Select Promiscuous Epitopes from Schistosoma mansoni , 2016, Applied Biochemistry and Biotechnology.

[5]  Vladimir Brusic,et al.  Bioinformatics for characterisation of allergens, allergenicity and allergic crossreactivity. , 2003, Trends in immunology.

[6]  Alberto Parra,et al.  Identification of Novel Vaccine Candidates against Campylobacter through Reverse Vaccinology , 2016, Journal of immunology research.

[7]  C DeLisi,et al.  T-cell antigenic sites tend to be amphipathic structures. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Pele Chong,et al.  Development of a full-length cDNA-derived enterovirus A71 vaccine candidate using reverse genetics technology. , 2016, Antiviral research.

[9]  Rodrigo Weber dos Santos,et al.  Computational modeling of the immune response to yellow fever , 2016, J. Comput. Appl. Math..

[10]  R. Rappuoli,et al.  Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design , 2016, The Journal of experimental medicine.

[11]  Marcelo Lobosco,et al.  Mathematical modeling based on ordinary differential equations: A promising approach to vaccinology , 2017, Human vaccines & immunotherapeutics.

[12]  S. Khalili,et al.  ILP-2 modeling and virtual screening of an FDA-approved library:a possible anticancer therapy. , 2016, Turkish journal of medical sciences.

[13]  D. Lauffenburger,et al.  Applying computational modeling to drug discovery and development. , 2006, Drug discovery today.

[14]  K. Rajewsky,et al.  The bulk of endogenously produced IgG2a is eliminated from the serum of adult C57BL/6 mice with a half‐life of 6–8 days , 1986, European journal of immunology.

[15]  Klaus Rajewsky,et al.  The half‐lives of serum immunoglobulins in adult mice , 1988, European journal of immunology.

[16]  Francesco Pappalardo,et al.  Computational modelling approaches to vaccinology. , 2015, Pharmacological research.

[17]  Jens Meiler,et al.  Ligand-based virtual screen for the discovery of novel M5 inhibitor chemotypes. , 2016, Bioorganic & medicinal chemistry letters.

[18]  Pedro A Reche,et al.  Prediction of MHC-peptide binding: a systematic and comprehensive overview. , 2009, Current pharmaceutical design.

[19]  Ryan P. Adams,et al.  Design of efficient molecular organic light-emitting diodes by a high-throughput virtual screening and experimental approach. , 2016, Nature materials.

[20]  R. Nogueira,et al.  17DD yellow fever vaccine , 2013, Reactions Weekly.

[21]  Xiaomin Luo,et al.  Discovery of Novel Inhibitors Targeting the Menin-Mixed Lineage Leukemia Interface Using Pharmacophore- and Docking-Based Virtual Screening , 2016, J. Chem. Inf. Model..

[22]  Darren R. Flower,et al.  Immunoinformatics and Computational Vaccinology: A Brief Introduction , 2007, In Silico Immunology.

[23]  Ana Paula Couto da Silva,et al.  Duration of post-vaccination immunity against yellow fever in adults. , 2014, Vaccine.

[24]  Luiz Antonio Bastos Camacho,et al.  Subdoses of 17DD yellow fever vaccine elicit equivalent virological/immunological kinetics timeline , 2014, BMC Infectious Diseases.

[25]  Dirk Linke,et al.  Reverse Vaccinology: The Pathway from Genomes and Epitope Predictions to Tailored Recombinant Vaccines. , 2016, Methods in molecular biology.

[26]  T. Monath,et al.  Yellow fever vaccine , 2005, Expert review of vaccines.

[27]  Michael A. Gonzalez,et al.  From genome to vaccine: in silico predictions, ex vivo verification. , 2001, Vaccine.

[28]  Randall J. LeVeque,et al.  Finite difference methods for ordinary and partial differential equations - steady-state and time-dependent problems , 2007 .

[29]  A. Barrett,et al.  Yellow fever vaccine , 2005, Expert review of vaccines.

[30]  Vitaly V. Ganusov,et al.  Mathematical modeling provides kinetic details of the human immune response to vaccination , 2015, Front. Cell. Infect. Microbiol..

[31]  Matthias Niedrig,et al.  Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: A model of human flavivirus infection , 1998, Journal of medical virology.

[32]  A. Perelson,et al.  Simulation and Prediction of the Adaptive Immune Response to Influenza A Virus Infection , 2009, Journal of Virology.

[33]  Darren R. Flower,et al.  Bioinformatics for Vaccinology , 2008 .

[34]  William Martin,et al.  Epitope-Based Immunome-Derived Vaccines: A Strategy for Improved Design and Safety , 2008, Clinical Applications of Immunomics.

[35]  Max Theiler,et al.  THE USE OF YELLOW FEVER VIRUS MODIFIED BY IN VITRO CULTIVATION FOR HUMAN IMMUNIZATION , 1937, The Journal of experimental medicine.

[36]  M. Maurin,et al.  REVIEW ARTICLE doi: 10.1111/j.1472-8206.2008.00633.x The Hill equation: a review of its capabilities in pharmacological modelling , 2008 .

[37]  L. Goldani,et al.  Yellow fever outbreak in Brazil, 2017 , 2017, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.